
Michael Ostacher critically appraises and summarises a recent Cochrane systematic review, which presents the latest best evidence on the efficacy of lamotrigine in the maintenance treatment of bipolar disorder.
[read the full story...]Michael Ostacher critically appraises and summarises a recent Cochrane systematic review, which presents the latest best evidence on the efficacy of lamotrigine in the maintenance treatment of bipolar disorder.
[read the full story...]Dean Connolly looks at an international study which asks: Is there consensus across evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?
[read the full story...]Keir Harding prepares for the #BIGSPD19 conference by reading Mike Crawford et al’s recent RCT on the clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder.
[read the full story...]Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?
[read the full story...]